Shanghai Hepu Biotechnology

Hepu Biotech is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the development of innovative RNA interference (RNAi) therapeutics. The company utilizes its proprietary Hepu-S platform, which features advanced GalNAc-siRNA conjugation technology, to deliver stable and potent gene-silencing drugs to the liver. Its lead candidate, HP-001, is currently in Phase 1 clinical trials for the treatment of chronic Hepatitis B, aiming to achieve a functional cure. Hepu Biotech is also advancing a robust pipeline of siRNA candidates targeting metabolic and cardiovascular diseases, such as hyperlipidemia and dyslipidemia. By focusing on precision genetic medicine, the company seeks to provide transformative treatments for patients with high unmet medical needs globally.